ArticleBlood advances2023

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.

Matthew J Frigault et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.